MA33052B1 - Variants de liaison anti-albumine sérique améliorés - Google Patents

Variants de liaison anti-albumine sérique améliorés

Info

Publication number
MA33052B1
MA33052B1 MA34105A MA34105A MA33052B1 MA 33052 B1 MA33052 B1 MA 33052B1 MA 34105 A MA34105 A MA 34105A MA 34105 A MA34105 A MA 34105A MA 33052 B1 MA33052 B1 MA 33052B1
Authority
MA
Morocco
Prior art keywords
serum albumin
contrasts
albumin enhancer
antagonist
antagonist serum
Prior art date
Application number
MA34105A
Other languages
Arabic (ar)
English (en)
Inventor
Angelis Elena De
Carolyn Enever
Haiqun Liu
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33052B1 publication Critical patent/MA33052B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des variants améliorés du domaine variable unique DOM7h-14 de l'immunoglobuline anti-albumine sérique, ainsi que des ligands et des conjugués de médicaments contenant de tels variants, des compositions, des acides nucléiques, des vecteurs et des hôtes.
MA34105A 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés MA33052B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16399009P 2009-03-27 2009-03-27
PCT/EP2010/052007 WO2010094722A2 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Publications (1)

Publication Number Publication Date
MA33052B1 true MA33052B1 (fr) 2012-02-01

Family

ID=42306619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34105A MA33052B1 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Country Status (23)

Country Link
US (2) US9175071B2 (fr)
EP (1) EP2398825B1 (fr)
JP (1) JP5766616B2 (fr)
KR (1) KR101820968B1 (fr)
CN (2) CN105061593B (fr)
AR (1) AR075506A1 (fr)
AU (2) AU2010215481C1 (fr)
BR (1) BRPI1008705B1 (fr)
CA (1) CA2753130C (fr)
CL (1) CL2011002023A1 (fr)
CO (1) CO6450689A2 (fr)
DO (1) DOP2011000269A (fr)
EA (1) EA027866B1 (fr)
ES (1) ES2654929T3 (fr)
IL (1) IL214481A0 (fr)
MA (1) MA33052B1 (fr)
MX (1) MX2011008752A (fr)
PE (1) PE20120170A1 (fr)
SG (1) SG173488A1 (fr)
TW (1) TW201042041A (fr)
UY (1) UY32452A (fr)
WO (1) WO2010094722A2 (fr)
ZA (1) ZA201105658B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063818A2 (fr) * 2008-12-05 2010-06-10 Glaxo Group Limited Procédés de sélection de polypeptides résistants aux protéases
ES2655071T3 (es) 2009-02-19 2018-02-16 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
PE20120514A1 (es) * 2009-03-27 2012-05-14 Glaxo Group Ltd Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
EA201291009A1 (ru) * 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
EA201390450A1 (ru) * 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
WO2012072731A2 (fr) 2010-12-01 2012-06-07 Glaxo Group Limited Domaines variables améliorés à liaison unique d'anti-albumine sérique
WO2012104227A1 (fr) 2011-02-02 2012-08-09 Glaxo Group Limited Nouvelles protéines de liaison à un antigène
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3551647A4 (fr) 2016-12-09 2021-01-13 Gliknik Inc. Optimisation de la fabrication de gl-2045, stradomère multimérisant
PL3583125T3 (pl) 2017-02-16 2025-07-28 Sonnet BioTherapeutics, Inc. Białka fuzyjne domeny wiążącej albuminę
WO2018224439A1 (fr) * 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-hsa
IL271127B2 (en) * 2017-06-05 2024-10-01 Numab Therapeutics AG Novel anti-hsa antibodies
CA3098165A1 (fr) 2018-04-24 2019-10-31 National Research Council Of Canada Anticorps de liaison a l'albumine serique pour extension de demi-vie reglable de produits biologiques
KR102204315B1 (ko) * 2018-11-16 2021-01-18 한국세라믹기술원 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도
AU2021397734A1 (en) * 2020-12-08 2023-07-06 Janux Therapeutics, Inc. Half-life extending compositions and methods
WO2024097639A1 (fr) * 2022-10-31 2024-05-10 Modernatx, Inc. Anticorps se liant à hsa et protéines de liaison et leurs utilisations
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025217497A1 (fr) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Protéines de liaison à l'albumine et méthodes d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713272A1 (de) 1997-03-29 1998-10-08 Junghans Uhren Gmbh Zeitzonen-Uhr
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1600459A3 (fr) 2002-06-28 2005-12-07 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
PL1737962T3 (pl) 2004-03-24 2011-02-28 Domantis Ltd Uniwersalny lider GAS1
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20090111745A1 (en) 2004-12-02 2009-04-30 Domantis Limited Plad Domain Peptides With Increased Serum Half Life Due To Conjugation To Domain Antibodies
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
WO2007085814A1 (fr) 2006-01-24 2007-08-02 Domantis Limited Protéines de fusion contenant des jonctions naturelles
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
JP2012509658A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Ｉｌ−１３に結合するリガンド

Also Published As

Publication number Publication date
AU2014202764B2 (en) 2016-07-07
AU2010215481C1 (en) 2015-06-04
BRPI1008705A2 (pt) 2016-03-08
WO2010094722A2 (fr) 2010-08-26
UY32452A (es) 2010-09-30
DOP2011000269A (es) 2011-12-31
CN105061593B (zh) 2018-08-03
CN102405232A (zh) 2012-04-04
SG173488A1 (en) 2011-09-29
ES2654929T3 (es) 2018-02-15
IL214481A0 (en) 2011-09-27
CO6450689A2 (es) 2012-05-31
KR20110127224A (ko) 2011-11-24
BRPI1008705B1 (pt) 2021-05-25
CL2011002023A1 (es) 2012-04-09
WO2010094722A3 (fr) 2011-01-13
US20110300158A1 (en) 2011-12-08
ZA201105658B (en) 2012-05-25
MX2011008752A (es) 2011-09-06
US20160075774A1 (en) 2016-03-17
AR075506A1 (es) 2011-04-06
CN102405232B (zh) 2015-08-19
EP2398825A2 (fr) 2011-12-28
PE20120170A1 (es) 2012-03-21
CN105061593A (zh) 2015-11-18
CA2753130C (fr) 2020-07-14
JP5766616B2 (ja) 2015-08-19
AU2010215481B2 (en) 2014-02-20
JP2012517819A (ja) 2012-08-09
EA201171067A1 (ru) 2012-02-28
EA027866B1 (ru) 2017-09-29
KR101820968B1 (ko) 2018-01-23
AU2010215481A1 (en) 2011-08-25
CA2753130A1 (fr) 2010-08-26
US9175071B2 (en) 2015-11-03
US9751935B2 (en) 2017-09-05
TW201042041A (en) 2010-12-01
AU2014202764A1 (en) 2014-06-12
EP2398825B1 (fr) 2017-10-25

Similar Documents

Publication Publication Date Title
MA33051B1 (fr) Variants de liaison anti-albumine serique ameliores
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
IN2012DN00640A (fr)
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EP2152290A4 (fr) Méthodes pour administrer des anticorps anti-il-5
EP2560684A4 (fr) Échafaudages multimériques à base de domaine de fibronectine de type iii
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EP1977763A4 (fr) Préparation stabilisatrice contenant des anticorps
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
EA201170441A1 (ru) Терапевтические противовирусные пептиды
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UA107836C2 (uk) Метод лікування хвороби альцгеймера
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
CR20110472A (es) Variantes de unión a anti-albumina de suero mejoradas